Measuring cognition and function in the preclinical stage of Alzheimer's disease

Sandra Weintraub, Maria C. Carrillo, Sarah Tomaszewski Farias, Terry E. Goldberg, James A. Hendrix, Judith Jaeger, David S Knopman, Jessica B. Langbaum, Denise C. Park, Michael T. Ropacki, Sietske A.M. Sikkes, Kathleen A. Welsh-Bohmer, Lisa J. Bain, Robert Brashear, Kumar Budur, Ana Graf, Ferenc Martenyi, Marta Segardahl Storck, Christopher Randolph

Research output: Contribution to journalShort survey

10 Citations (Scopus)

Abstract

The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

Original languageEnglish (US)
Pages (from-to)64-75
Number of pages12
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cognition
Alzheimer Disease
Amyloid
Disease Progression
Research
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Measuring cognition and function in the preclinical stage of Alzheimer's disease. / Weintraub, Sandra; Carrillo, Maria C.; Farias, Sarah Tomaszewski; Goldberg, Terry E.; Hendrix, James A.; Jaeger, Judith; Knopman, David S; Langbaum, Jessica B.; Park, Denise C.; Ropacki, Michael T.; Sikkes, Sietske A.M.; Welsh-Bohmer, Kathleen A.; Bain, Lisa J.; Brashear, Robert; Budur, Kumar; Graf, Ana; Martenyi, Ferenc; Storck, Marta Segardahl; Randolph, Christopher.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 4, 01.01.2018, p. 64-75.

Research output: Contribution to journalShort survey

Weintraub, S, Carrillo, MC, Farias, ST, Goldberg, TE, Hendrix, JA, Jaeger, J, Knopman, DS, Langbaum, JB, Park, DC, Ropacki, MT, Sikkes, SAM, Welsh-Bohmer, KA, Bain, LJ, Brashear, R, Budur, K, Graf, A, Martenyi, F, Storck, MS & Randolph, C 2018, 'Measuring cognition and function in the preclinical stage of Alzheimer's disease', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 4, pp. 64-75. https://doi.org/10.1016/j.trci.2018.01.003
Weintraub, Sandra ; Carrillo, Maria C. ; Farias, Sarah Tomaszewski ; Goldberg, Terry E. ; Hendrix, James A. ; Jaeger, Judith ; Knopman, David S ; Langbaum, Jessica B. ; Park, Denise C. ; Ropacki, Michael T. ; Sikkes, Sietske A.M. ; Welsh-Bohmer, Kathleen A. ; Bain, Lisa J. ; Brashear, Robert ; Budur, Kumar ; Graf, Ana ; Martenyi, Ferenc ; Storck, Marta Segardahl ; Randolph, Christopher. / Measuring cognition and function in the preclinical stage of Alzheimer's disease. In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2018 ; Vol. 4. pp. 64-75.
@article{f92e4ee0e402451da99c72c6b4242688,
title = "Measuring cognition and function in the preclinical stage of Alzheimer's disease",
abstract = "The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.",
author = "Sandra Weintraub and Carrillo, {Maria C.} and Farias, {Sarah Tomaszewski} and Goldberg, {Terry E.} and Hendrix, {James A.} and Judith Jaeger and Knopman, {David S} and Langbaum, {Jessica B.} and Park, {Denise C.} and Ropacki, {Michael T.} and Sikkes, {Sietske A.M.} and Welsh-Bohmer, {Kathleen A.} and Bain, {Lisa J.} and Robert Brashear and Kumar Budur and Ana Graf and Ferenc Martenyi and Storck, {Marta Segardahl} and Christopher Randolph",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.trci.2018.01.003",
language = "English (US)",
volume = "4",
pages = "64--75",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Measuring cognition and function in the preclinical stage of Alzheimer's disease

AU - Weintraub, Sandra

AU - Carrillo, Maria C.

AU - Farias, Sarah Tomaszewski

AU - Goldberg, Terry E.

AU - Hendrix, James A.

AU - Jaeger, Judith

AU - Knopman, David S

AU - Langbaum, Jessica B.

AU - Park, Denise C.

AU - Ropacki, Michael T.

AU - Sikkes, Sietske A.M.

AU - Welsh-Bohmer, Kathleen A.

AU - Bain, Lisa J.

AU - Brashear, Robert

AU - Budur, Kumar

AU - Graf, Ana

AU - Martenyi, Ferenc

AU - Storck, Marta Segardahl

AU - Randolph, Christopher

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

AB - The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

UR - http://www.scopus.com/inward/record.url?scp=85042848973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042848973&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2018.01.003

DO - 10.1016/j.trci.2018.01.003

M3 - Short survey

AN - SCOPUS:85042848973

VL - 4

SP - 64

EP - 75

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

ER -